ALLOCSC-01 / Takeda - LARVOL DELTA

Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients with ST-segment Elevation Myocardial Infarction and Left Ventricular Dysfunction: A Multicenter Randomized, Double-Blind and Placebo-Controlled Clinical Trial. (PubMed, Circ Res) - P1/2; "Allogeneic cardiac stem cells (AlloCSC-01) have shown protective, immunoregulatory, and regenerative properties with a robust safety profile in large animal models of heart disease...Allogeneic cardiac stem cells can be safely administered in STEMI patients with LV dysfunction early after revascularization. Low immunogenicity and absence of immune-mediated events will facilitate adequately powered studies to demonstrate their clinical efficacy in this setting.Clinical Trial Registration: NCT 02439398."

Clinical • Journal

"Mar 2018 (CTX101) vs Mar 2019 (CTX110) $CRSP" (@JacobPlieth)

"Anyone know the difference between CTX101 and CTX110? $CRSP" (@JacobPlieth)